Synendos Therapeutics
PrivateLast Round
Grant
Oct 30, 2024
Total Funding Raised
$32.2M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Synendos Therapeutics operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a Grant round in October 2024.
Synendos Therapeutics is a neuroscience company developing therapies for neuropsychiatric and neurological disorders by modulating the endocannabinoid system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Synendos Therapeutics Comparables
Compare Synendos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| H. Lundbeck A/S | 77% | |
| EmpowerPharm Inc. | 76% | |
| Roche Holding | 71% |
For institutional investors. Book with your work email.
Synendos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 30, 2024 | ||||
| Grant | Apr 20, 2021 | ||||
| Series A | Nov 12, 2020 | ||||
| Grant | Oct 1, 2020 | ||||
| Grant | Nov 1, 2019 | ||||
Grant | Aug 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Synendos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gebert Rüf Stiftung | Grant |
| Ysios Capital | Series A, Grant |
| Eurostars SME programme | Grant |
| BERNINA BioInvest AG | Series A |
| Innosuisse | Grant |
| BaseLaunch | Accelerator |
| Sunstone Life Science Ventures | Grant, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 76% MoM.
- Aug 12, 2025
Dr. George Garibaldi appointed as new Chief Medical Officer.
For institutional investors. Book with your work email.
Synendos Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Synendos Therapeutics's valuation, stock price, and market status.
Is Synendos Therapeutics a public or private company?
Synendos Therapeutics is a private company.
What is the current stock price of Synendos Therapeutics?
Synendos Therapeutics is a private company, so its shares have no public market price. Caplight tracks Synendos Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Synendos Therapeutics worth (valuation)?
Valuation information for Synendos Therapeutics is not publicly available.
Can I buy Synendos Therapeutics stock?
Synendos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Synendos Therapeutics's last funding round?
Synendos Therapeutics's most recent funding round was Grant on October 30, 2024.
Who are the main investors in Synendos Therapeutics?
Key investors in Synendos Therapeutics include Ysios Capital, BaseLaunch, Sunstone Life Science Ventures, Kurma Partners.
Will Synendos Therapeutics IPO soon?
No public IPO plans have been announced for Synendos Therapeutics.
How can I track Synendos Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Synendos Therapeutics's shares on secondary markets.